medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2008, Number 5

<< Back Next >>

Rev Mex Urol 2008; 68 (5)

Epidemiological aspects of transrectal prostate biopsies in the Hospital General “Dr. Manuel Gea Gonzalez”

Fernández-Carreño AJ, Andrade-Platas JD, Morales-Montor JG, Pacheco-Gahbler C, Calderón-Ferro F

Language: Spanish
References: 17
Page: 257-261
PDF size: 150.99 Kb.


ABSTRACT

Background: Ultrasound-guided transrectal prostate biopsy has become the method of choice for prostate cancer diagnosis since Hodge proposed the system of sextants. However, the value of this technique has recently been questioned, since cancer is detected in only 30% of the biopsies performed. This has led to the proposal of taking 8 to 13 fragments.
Objective: To identify patient characteristics and their variables and compare them with prostate biopsy results and consequent disease treatment and progression. Materials and methods: This cross-sectional study utilized the Urology Service database to gather case records of patients having undergone prostate biopsy from January 1998 to September 2007. Specific variables of the prostate biopsies were then taken from the clinical files.
Results: A total of 747 case records of patients having undergone prostate biopsy over a period of 9 years were reviewed. Mean age was 72.7 years (45 to 97 year range). Three hundred seventy-five patients (50.2%) were cancer positive, 199 were managed with hormonal treatment and 176 with radical surgery.
Conclusions: There is a high probability of cancer detection in the first biopsy series with minimum morbidity in properly selected patients.


REFERENCES

  1. Karakiewicz P, Benayoun S, Catan M. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol 1995;173:1930-1934.

  2. Siu W, Duna R, Shah R. Use of extended pattern technique for initial prostate biopsy. J Urol 2005;174:505-509.

  3. Eskicorapci S, Guliyev F, Akdogan B. Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection. J Urol 2005;173:1536-1540.

  4. Eggener S, Rohel K, Catalona W. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/mL and an initially negative biopsy. J Urol 2005;174:500-504.

  5. Remzi M, Fong Y, Dobrovitz M. Validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol 2005;174:1256-1261.

  6. Chan T, Epstein J. Patient and urologist driven second opinion of prostate needle biopsies. J Urol 2005;174:1390-1394.

  7. Konig K, Scheipers U, Pesavento A. Initial experiences with real time elastography guided prostate biopsies. J Urol 2005;174(1):115-117.

  8. King Ch, Patel D, Terris M. Prostate biopsy volume indices do not predict for significant Gleason Upgrading. Am J Clin Oncol 2005;28(2):125-129.

  9. Gong S, Chen J, Lavoipierre A. Predictive modeling of initial biopsy outcomes using age, PSA, PSAD, DRE and TRUS findings in 889 episodes. BJU Intl 2006;9(Suppl).

  10. Kennedy-Smith A, Jayathillake A, Shaw L. Direct access prostate biopsies: is prior clinic assessment necessary? BJU Intl 2005;9 (17 Suppl 1).

  11. Yanke B, Gonen M, Scardino P. Validation of a nomogram for predicting positive repeat biopsy for prostate cancer. J Urol 2005;173(2):421-424.

  12. McNaughton M, Barry M, Caubet J. Validity of primary care patient self report of abnormal prostate biopsy results. J Urol 2004;172(6):2366-2368.

  13. Gomez F, Barbagelata A, Castelo L. Value of the percentage of positive cores in prostatic biopsy to predict biochemical recurrence alter radical prostatectomy. BJU Intl 2004;94(Suppl 2).

  14. Crawford E, Maroni P, Donohue R. Previous negative prostate biopsies predict codger Gleason grade and codger percentage of positive cores in patients with cancer. BJU Intl 2004;94(Suppl 2).

  15. Boddy JL, Dev S, Pike DJ, Malone PR. Intra Individual variation of serum prostate specific antigen levels in men with benign prostate biopsies. BJU Int 2004;93(6):735-8.

  16. Damico A, Renshaw A, Cote K. Impact on the percentage of positive prostate cores on prostate cancer specific mortality for patients with low or favorable intermediate risk disease. J Clin Oncol 2004;22(18):3726-3732.

  17. Kommu S, Lau DH, Hadway P, Patel S, Persad RA, Watkin NA. Increasing prostate biopsy cores based on volume vs. the sextant biopsy: a prospective randomized controlled clinical study on cancer detection rates and morbidity. BJU Int. 2004;94(7):1145.




2020     |     www.medigraphic.com